Companies: 10,795·Total market cap: $144.5T
Statera Biopharma, Inc.

Statera Biopharma, Inc.

STABOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$7142
P/E Ratio
52W High$0.0266
52W Low$0.0001

Statera Biopharma, Inc. (STAB) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

STAB · cash on hand · updated Dec 31, 2021

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$2.0M +233.3% vs prior year
FY · as of Dec 31, 2021 · Reported in USD
Cash & Cash Equiv. (CCE)
$1.8M
cashAndCashEquivalents
Short-Term Investments
$134,603
shortTermInvestments
YoY Change vs Prior Year
+233.3%
vs prior fiscal year
Latest Quarter
$506,098
Q3 2022
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2021

Net cash vs debt

Cash & ST Investments$2.0MCash on Hand
Total Debt$16.3MTotal Debt
Net Cash / Net Debt−$14.3MNet Debt Position
Cash vs Debt Ratio
Cash 11%Debt 89%

Statera Biopharma, Inc. carries a net debt position of $14.3M. Total debt ($16.3M) exceeds cash on hand ($2.0M). Statera Biopharma, Inc. cash vs debt ratio: 11% cash / 89% debt.

Net Cash = Cash & ST Investments − Total Debt$2.0M$16.3M = −$14.3M

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
STAB annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2021Latest$2.0M+233.3%
Dec 31, 2020$0.6M-62.4%
Dec 31, 2019$1.6M-61.7%
Dec 31, 2018$4.1M-53.1%
Dec 31, 2017$8.8M-42.3%
STAB cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.6%
#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%
#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%
#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
Statera Biopharma, Inc.
Statera Biopharma, Inc.YOU
STAB
$2.0M27714.0%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Statera Biopharma, Inc. (STAB) cash on hand as of December 31, 2021 is $2.0M, comprising $1.8M in cash and cash equivalents (CCE) plus $134,603 in short-term investments — reported as Statera Biopharma, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Statera Biopharma, Inc. cash reserves or cash position.

Statera Biopharma, Inc. annual cash on hand history shows increased +233.3% in 2021: increased +233.3% in 2021. Statera Biopharma, Inc. cash reserves in 2021 reflect the company's capital allocation strategy.

Statera Biopharma, Inc. carries total debt of $16.3M against cash of $2.0M, resulting in a net debt position of -$14.3M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Frequently asked questions

STAB cash on hand · 5 questions

As of December 31, 2021, Statera Biopharma, Inc. (STAB) has $1,979,335 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $1,844,732 in cash and cash equivalents (CCE) plus $134,603 in short-term investments. Latest quarter (September 30, 2022): $506,098. Data sourced from the annual 10-K filing via FMP.

STAB cash on handSTAB cash reservesSTAB cash 2021how much cash does STAB have

Source: FMP /balance-sheet-statement · US GAAP · Statera Biopharma, Inc. · Statera Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2021